Skip to content
Screener

4D Molecular Therapeutics FDMT Operating Lease Liabilities (Total)

Operating Lease Liabilities (Total) at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$266.8M+13.8%
EyePoint, Inc. logo
EyePoint, Inc.EYPT
$22.37M-5.7%
KLR
Kalaris TherapeuticsKLRS
$1.41M
MeiraGTx Holdings plc logo
MeiraGTx Holdings plcMGTX
$12.83M+73.8%
Prime Medicine logo
Prime MedicinePRME
$112.48M-6.1%
Savara logo
SavaraSVRA
$1.09M

Other financials

Income statement

See full
Revenue$3.0M+21,664%
Operating income-$73.6M-37.3%
Net income-$68.8M-43.3%
EPS (diluted)-$1.01-17.4%

Balance sheet

See full
Cash & equivalents$72.5M-45.7%
Total debt$20.5M-13.9%
Total equity$451.8M-3.8%
Total assets$512.9M-0.5%

Cash flow

See full
Operating cash flow-$68.1M-42.6%
CapEx--100%
Free cash flow-$68.1M-40.8%

Valuation

See full
Market cap$582.36M+127%
Enterprise value$530.4M+162%
P/S6.6×-7,757×

Profitability

See full
Operating margin-220.1%-110pp
Net margin-174,314.2%-62,763pp
FCF margin-154,209.2%-53,057pp

Returns & leverage

See full
Return on equity-45.4%+29.8pp
Debt / equity0.0×
Current ratio9.3×-3.0×

Where this comes from

Reported directly by 4D Molecular Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiability.

The source filing: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:13 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-211939
20285,510
20295,675
20305,455
Total future minimum lease payments26,155
Less: Amount representing interest(5,620)
Present value of future minimum lease payments20,535
Less: Current portion of operating lease liabilities(5,486)
Long-term portion of operating lease liabilities$15,049

Item 1. Condensed Financial Statements (Unaudited)

FAQ

What is 4D Molecular Therapeutics's operating lease liabilities (total)?
4D Molecular Therapeutics (FDMT) reported operating lease liabilities (total) of $20.54M in Q1 2026.
How has 4D Molecular Therapeutics's operating lease liabilities (total) changed year-over-year?
4D Molecular Therapeutics's operating lease liabilities (total) decreased by 13.9% year-over-year, from $23.85M to $20.54M.
What is the long-term trend for 4D Molecular Therapeutics's operating lease liabilities (total)?
Over 4 years (2021 to 2025), 4D Molecular Therapeutics's operating lease liabilities (total) has grown at a 6.8% compound annual growth rate (CAGR), from $16.45M to $21.41M.
What does operating lease liabilities (total) mean?
This represents the total present value of future lease payments for operating leases, recognized as a liability on the balance sheet. It reflects the company's long-term commitment to leased assets such as office space, warehouses, and equipment. Tracking this helps investors evaluate the company's off-balance-sheet financing obligations and overall debt-like commitments.

Ask your AI about 4D Molecular Therapeutics's operating lease liabilities (total).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude